Matthias Kretzler

Title: Matthias Kretzler: Innovator in Renal Disease Research

Introduction

Matthias Kretzler is a prominent inventor based in Ann Arbor, MI (US). He has made significant contributions to the field of renal disease research, holding 2 patents that focus on innovative methods for predicting disease progression and treatment.

Latest Patents

Kretzler's latest patents include groundbreaking work on biomarkers and methods for progression prediction for chronic kidney disease (CKD). This invention involves identifying biomarkers that indicate an increased risk of CKD progression and monitoring therapy effectiveness through the detection of levels of NTpro BNP, EGF, Apo H, GDF-15, and the albumin-to-creatinine ratio. Another notable patent is related to ILK inhibitors for the treatment of renal disease. This invention addresses renal diseases using modulators of integrin linked kinase, offering methods of treatment and therapeutic agents such as antisense, small molecules, catalytic peptides, and antibodies. These agents can be combined with traditional therapies, including ACE inhibitors, to treat the underlying causes of renal disease rather than merely alleviating symptoms.

Career Highlights

Throughout his career, Kretzler has worked with notable organizations, including QLT Inc. and the University of Michigan. His work has significantly advanced the understanding and treatment of renal diseases, showcasing his commitment to improving patient outcomes.

Collaborations

Kretzler has collaborated with esteemed colleagues, including Laura Badi and Hanno Langen, further enhancing the impact of his research in the field of renal health.

Conclusion

Matthias Kretzler's innovative contributions to renal disease research through his patents and collaborations highlight his dedication to advancing medical science. His work continues to pave the way for improved treatment options and better patient care in the realm of chronic kidney disease.